Clinical Trials

375 enrolled

DermatologicGynecologic

Uveal Melanoma, Melanoma, Neoplasms, Ovarian Neoplasms, Recurrence

NCT05257590 2026-04-13

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

95 enrolled

Carcinoma, Hepatocellular, Neoplasms

NCT05919264 2026-04-09

FOG-001 in Locally Advanced or Metastatic Solid Tumors

CNSGastrointestinalGenitourinaryGynecologicSarcoma

595 enrolled

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT03505320 2026-04-03

ILUSTRO

Phase 2 Active not recruiting

143 enrolled

Neoplasms, Stomach Neoplasms

NCT05533697 2026-04-03

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

361 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT07276373 2026-04-03

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

50 enrolled

Phase 1 Not yet recruiting

Neoplasms

NCT07476326 2026-04-03

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

120 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms

NCT02693535 2026-04-02

TAPUR

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT03899155 2026-04-01

Pan Tumor Rollover Study

1,500 enrolled

Neoplasms

NCT06031233 2026-03-30

MINUTE

Phase 4 Recruiting

776 enrolled

Neoplasms

NCT04336241 2026-02-27

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

BreastDermatologicGastrointestinalThoracic

36 enrolled

Uveal Melanoma, Breast Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasms

NCT03400332 2026-02-24

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Phase 1/2 Completed

281 enrolled 44 charts

Melanoma, Neoplasms

NCT03388190 2026-02-13

METIMMOX

80 enrolled 13 charts

Phase 1/2 Active not recruiting

Neoplasm Metastasis, Neoplasms

NCT04078295 2026-02-10

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

125 enrolled

Neoplasms

NCT06880549 2026-02-05

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors

57 enrolled

Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence

NCT02813135 2026-01-16

ESMART

472 enrolled

Neoplasms

NCT06764771 2025-12-17

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

GastrointestinalGenitourinaryThoracic

437 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasms, Colorectal Neoplasms

NCT02812667 2025-11-12

Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

18 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT02817633 2025-10-28

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

DermatologicGastrointestinalThoracic

463 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

NCT05407675 2025-10-03

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Phase 1/2 Completed

68 enrolled 27 charts

Phase 2 Active not recruiting

Neoplasms

NCT04095208 2025-10-02

CONGRATS

67 enrolled

Sarcoma

Tertiary Lymphoid Structures, Neoplasm Metastasis, Neoplasms, Sarcoma

NCT06463665 2025-09-26

VIRO-25

142 enrolled

Phase 3 Active not recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT03937219 2025-09-10

COSMIC-313

855 enrolled 12 charts

Phase 2/3 Active not recruiting

Carcinoma, Carcinoma, Renal Cell, Neoplasms

NCT03470922 2025-09-09

RELATIVITY-047

714 enrolled 17 charts 2 FDA

Melanoma, Neoplasms

NCT06237920 2025-09-03

TURANDORELA

90 enrolled

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Female Urogenital Diseases and Pregnancy Complications, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT02099058 2025-08-14

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

237 enrolled

Neoplasms

NCT03697564 2025-08-06

Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

2 enrolled 10 charts

Neoplasms, Pancreatic Neoplasms

NCT04572451 2025-08-01

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Phase 1 Recruiting

50 enrolled

Phase 3 Active not recruiting

Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site

NCT03522246 2025-06-24

ATHENA

1,097 enrolled 26 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

NCT05180799 2025-06-15

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Phase 1/2 Active not recruiting

320 enrolled

Phase 1/2 Active not recruiting

Melanoma, Neoplasm Metastasis, Neoplasms

NCT05888831 2025-06-11

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

100 enrolled

BreastThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Triple Negative Breast Neoplasms

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

39 enrolled

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT03387761 2025-03-05

NABUCCO

54 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT02966548 2025-02-17

Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

35 enrolled

Neoplasms

NCT03447470 2025-01-29

Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

46 enrolled 29 charts

Biliary Tract Neoplasms, Neoplasms, Thymus Neoplasms

NCT04350463 2025-01-22

A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

92 enrolled 25 charts

Neoplasms, Small Cell Lung Carcinoma

NCT03667716 2025-01-17

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

BreastGastrointestinalGynecologicThoracic

121 enrolled

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04109066 2025-01-08

CheckMate 7FL

Phase 3 Completed

521 enrolled 17 charts

Breast

Breast Neoplasms, Neoplasms

NCT02009449 2024-11-15

IVY

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

353 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03565445 2024-11-01

A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & Neck

190 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

NCT03296137 2024-10-26

Adoptive Cell Therapy Across Cancer Diagnoses

Phase 1/2 Completed

25 enrolled 9 charts

Neoplasms

NCT05655715 2024-10-16

CheckPRO

90 enrolled

Neoplasms, Prostatic Neoplasms

NCT03409198 2024-10-15

ICON

82 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT02664181 2024-09-03

PRECISE

13 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT03299946 2024-09-03

Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)

15 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT03190265 2024-08-07

Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer

61 enrolled 11 charts

Adenocarcinoma, Carcinoma, Neoplasms, Pancreatic Neoplasms

NCT06274437 2024-08-07

A Study of BND-35 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

280 enrolled

Neoplasms

NCT05898828 2024-08-05

Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer

Phase 1/2 Withdrawn

Esophageal Neoplasms, Neoplasms

NCT02848443 2024-07-25

Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer

78 enrolled